Title |
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
|
---|---|
Published in |
Quality of Life Research, August 2016
|
DOI | 10.1007/s11136-016-1388-1 |
Pubmed ID | |
Authors |
T. Shiroiwa, T. Fukuda, K. Shimozuma, M. Mouri, Y. Hagiwara, H. Doihara, H. Akabane, M. Kashiwaba, T. Watanabe, Y. Ohashi, H. Mukai |
Abstract |
The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. In the SELECT BC trial, patients were randomly allocated to the S-1 or taxane (paclitaxel or docetaxel) arm. Health status was assessed by EQ-5D at pre-treatment, 3 and 6 months after randomization, and every 6 months thereafter to the extent possible. Least square mean scores were assessed to compare EQ-5D index values between groups. Time to deterioration analysis was also performed by defining the minimally important difference of EQ-5D as 0.05 or 0.1. The number of patients for EQ-5D analysis was 175 and 208 in the taxane and S-1 arms, respectively. Least square mean EQ-5D index values up to 60 months were 0.741 (95 % CI [0.713-0.769]) in the taxane arm and 0.748 [0.722-0.775] in the S-1 arm. The EQ-5D index value during PFS up to 12 months in the S-1 was superior to the corresponding index value in the taxane (0.812 [0.789-0.834] vs. 0.772 [0.751-0.792], P = 0.009). Time to deterioration analysis also revealed that S-1 significantly delayed the deterioration of EQ-5D index value during the period before progression (P = 0.002 and 0.003). Our findings suggest that the EQ-5D index value was higher in patients treated with S-1 during first-line chemotherapy. Considering non-inferiority of S-1 in terms of OS, obtained quality-adjusted life years may be greater in the S-1 arm. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 4 | 44% |
United States | 1 | 11% |
Canada | 1 | 11% |
Unknown | 3 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 8 | 89% |
Scientists | 1 | 11% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 91 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 11 | 12% |
Student > Master | 9 | 10% |
Researcher | 9 | 10% |
Student > Ph. D. Student | 6 | 7% |
Student > Doctoral Student | 5 | 5% |
Other | 12 | 13% |
Unknown | 39 | 43% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 18% |
Nursing and Health Professions | 7 | 8% |
Psychology | 5 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
Biochemistry, Genetics and Molecular Biology | 3 | 3% |
Other | 8 | 9% |
Unknown | 47 | 52% |